scorecardresearch
Monday, July 21, 2025
TopicSinopharm

Topic: Sinopharm

China’s Sinopharm vaccine gets a seal of approval as JAMA publishes study of its success

The study says the two inactivated vaccines developed by Sinopharm prevented symptomatic infections by 72.8% & 78.1%, largely in-line with what the drugmaker previously announced.

With India & US stumbling, the world is turning to China for vaccines

Demand is expected to rise if WHO authorises China’s Sinovac & Sinopharm vaccines, allowing developing countries in Asia, Africa & Latin America to access them through Covax.

China opens mass domestic Covid inoculation drive to diplomats, foreign journalists

A notice issued to foreign journalists in Beijing Wednesday said they can get the Inactivated SARS-CoV-2 Vaccine, developed by Sinopharm's China National Biotec Group.

Chinese Covid vaccine maker CanSino to offer Pakistan 20 million doses

CanSino has applied for regulatory approval in Pakistan and will be give the country preferential access to the single-shot vaccine. Pakistan is yet to start its vaccination drive.

Bahrain approves registration of China’s Covid vaccine Sinopharm

The vaccine has already been administered to hundreds of thousands of people under emergency authorization in China, but it’s yet to receive public use approval from any drug regulators.

On Camera

India’s TRP ecosystem needs a reset. Time to end BARC monopoly

A ratings monopoly in India has led to lack of technological variation, resulting in sluggish systems detached from market dynamics.

India-US set to ink mini trade deal soon, reach understanding on agricultural & dairy products

Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.

Not just AK-203, India & Russia to jointly manufacture AK-19 and PPK-20 for domestic use and export 

India-Russia JV is also racing to deliver 7,000 more AK-203 assault rifles by 15 Aug. These are currently being made with 50% indigenisation and this will surge to 100% by 31 December.

Strategic partner one day, tactical nightmare the next: India’s learning Trumplomacy the hard way

Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.